Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced an update on the Phase III INTR@PID Lung 037 study and the extensive INTR@PID clinical trial program for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results